Navigation Links
Brazil's Rheumatoid Arthritis Drug Market Will Grow $115 Million by 2013
Date:7/20/2009

WALTHAM, Mass., July 20 /PRNewswire/ -- Decision Resources, one of the world's leading research and advisory firms focusing on pharmaceutical and healthcare issues, finds that the rheumatoid arthritis drug market in Brazil will grow from $200 million in 2008 to more than $315 million in 2013. The 2008 market leaders were the tumor necrosis factor-alpha (TNF-alpha) inhibitors Abbott's Humira and Schering-Plough's Remicade which recorded sales of $50 million and $43 million, respectively, despite a combined patient share of two percent. Wyeth's Enbrel, the third marketed agent from this class, recorded fewer sales because of its inconvenient dosing frequency and its availability only in a lyophilized form.

The new Emerging Markets report entitled Rheumatoid Arthritis in Brazil also finds that survey results of Brazilian rheumatologists show regional differences in their preferences for agents within key drug classes for rheumatoid arthritis. While Enbrel emerges as the patient share leader among biologics in Rio de Janeiro, rheumatologists from Sao Paulo and Belo Horizonte prefer Humira and Remicade, respectively.

"Competition among TNF-alpha inhibitors is influenced by a drug's clinical profile, order of market entry, ease of access in the public sector, patients' socioeconomic status, ease of administration and marketing campaigns," stated Irene Koulinska, Sc.D., M.D.

The new report is part of an expansion of the Emerging Markets report series to cover Brazil. The series contains primary research of physicians and epidemiology study in key pharmaceutical markets of Brazil--Rio de Janeiro, Sao Paulo and Belo Horizonte.

About Emerging Markets Reports

Decision Resources is the FIRST and ONLY company to offer a syndicated report series for high-growth emerging markets with comprehensive disease-specific analysis. Each report assesses the commercial opportunity in the pharmaceutical market for a disease based on population demographics, economic development, disease epidemiology and changing physicians' practices.

About Decision Resources

Decision Resources (www.DecisionResources.com) is a world leader in market research publications, advisory services and consulting designed to help clients shape strategy, allocate resources and master their chosen markets. Decision Resources is a Decision Resources, Inc. company.

About Decision Resources, Inc.

Decision Resources, Inc. is a cohesive portfolio of companies that offers best-in-class, high-value information and insights on important sectors of the healthcare industry. Clients rely on this analysis and data to make informed decisions. Please visit Decision Resources, Inc. at www.DecisionResourcesInc.com.

All company, brand or product names contained in this document may be trademarks or registered trademarks of their respective holders.

For more information, contact:

    Gisselle Morales                             Elizabeth Marshall
    Decision Resources                           Decision Resources, Inc.
    781-296-2691                                 781-296-2563
    gmorales@dresources.com                      emarshall@dresources.com


'/>"/>
SOURCE Decision Resources
Copyright©2009 PR Newswire.
All rights reserved

Related medicine news :

1. Chinas Rheumatoid Arthritis Drug Market Will More than Double by 2013
2. New Drug Promising Against Rheumatoid Arthritis
3. Over half of people with rheumatoid arthritis have periodontitis
4. Exercise improves functional and psycological ability and reduces steroid need in rheumatoid arthritis
5. Rheumatoid arthritis is associated with poor sleep in women
6. Rheumatoid Arthritis Drug Might Fight Swine Flu
7. Treating gum disease helps rheumatoid arthritis sufferers
8. For the Treatment of Rheumatoid Arthritis, Market Share for TNF-alpha Inhibitors Will Decrease Through 2018
9. Nektar Announces UCBs Cimzia(R) Approved by U.S. FDA for Adult Patients Suffering From Moderate to Severe Rheumatoid Arthritis
10. UCBs CIMZIA(R) (certolizumab pegol) Approved by the U.S. FDA for Adult Patients Suffering From Moderate to Severe Rheumatoid Arthritis
11. SIMPONI(TM) (golimumab) Receives FDA Approval as First Once-Monthly Anti-TNF for Treatment of Rheumatoid Arthritis, Psoriatic Arthritis and Ankylosing Spondylitis
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/26/2016)... ... May 26, 2016 , ... Memorial Day Weekend marks the unofficial start ... is sharing tips to make sure your family and vehicle are ready to hit ... there may be 439 deaths and an additional 50,500 serious injuries from motor vehicle ...
(Date:5/26/2016)... (PRWEB) , ... May 26, 2016 , ... North ... May 13 at Blackhorse Golf Club in Cypress. With the help of community partners, ... that restores, empowers, and renews hope for wounded service members and their families through ...
(Date:5/26/2016)... Scotch Plains, NJ (PRWEB) , ... May 26, ... ... year being recognized as an NJ Top Doc! Along with his wonderful accolades ... to excellence in podiatry. Congratulations, Dr. Batelli! , Dr. Eugene Batelli is ...
(Date:5/26/2016)... ... , ... On May 23rd during the National Eye Institute’s “Healthy Vision Month”, ... was honored by Ashram, Inc. as the world’s foremost water visionary. , “Sharon Kleyne ... of the Nile to fill their red clay pots with life-sustaining water.” Said Ashram ...
(Date:5/26/2016)... ... May 26, 2016 , ... ... Morrow-Fox . With over 20 years of experience in leading technology and human ... several years of university teaching, Morrow-Fox will be featured on Metcalf’s VoiceAmerica ...
Breaking Medicine News(10 mins):
(Date:5/25/2016)... PARIS , May 25,2016 ... with the near-infrared Cellvizio platform for urological and ... MKEA, OTCQX: MKEAY) inventor of Cellvizio®, the multidisciplinary ... important regulatory milestone in the US with the ... Food and Drug Administration (FDA). This new FDA ...
(Date:5/25/2016)... GERMANTOWN, Maryland , May 25, ... Therawis bedient dringenden Bedarf ... QIAGEN N.V. (NASDAQ: QGEN ; ... Lizenz- und Entwicklungsvereinbarung mit Therawis Diagnostics GmbH zur ... eingegangen zu sein. Ein erstes Projekt wird die ...
(Date:5/25/2016)...  Zymo Research Corp. announced today the final ... that help researchers obtain the most accurate and ... rapid growth of the study of microbiomes has ... methods to improve the reproducibility and quality of ... every step of the measurement process including collection ...
Breaking Medicine Technology: